浏览全部资源
扫码关注微信
1.北京中医药大学中药学院,北京 100029
2.北京中医药大学东方医院药学部,北京 100078
3.北京中医药大学东直门医院药学部,北京 100700
4.北京中医药大学东直门医院洛阳医院药学部,河南 洛阳 471934
Received:24 November 2024,
Revised:05 April 2025,
Accepted:23 April 2025,
Published:30 May 2025
移动端阅览
郭媛媛,马丽娜,蔺虎琴等.泽泻汤传统汤剂和配方颗粒降低脂质堆积的作用机制和药效研究 Δ[J].中国药房,2025,36(10):1202-1208.
GUO Yuanyuan,MA Lina,LIN Huqin,et al.Comparative study on the mechanism and efficacy of Zexie tang traditional decoction and formula granules in reducing lipid accumulation[J].ZHONGGUO YAOFANG,2025,36(10):1202-1208.
郭媛媛,马丽娜,蔺虎琴等.泽泻汤传统汤剂和配方颗粒降低脂质堆积的作用机制和药效研究 Δ[J].中国药房,2025,36(10):1202-1208. DOI: 10.6039/j.issn.1001-0408.2025.10.09.
GUO Yuanyuan,MA Lina,LIN Huqin,et al.Comparative study on the mechanism and efficacy of Zexie tang traditional decoction and formula granules in reducing lipid accumulation[J].ZHONGGUO YAOFANG,2025,36(10):1202-1208. DOI: 10.6039/j.issn.1001-0408.2025.10.09.
目的
2
通过网络药理学探究泽泻汤降低脂质堆积的作用机制,并比较泽泻汤传统汤剂、配方颗粒降低脂质堆积的药效差异。
方法
2
采用TCMSP、SwissTargetPrediction数据库检索泽泻汤活性成分和靶点;采用GeneCards、OMIM、DisGeNET、TTD数据库分析非酒精性脂肪性肝病(NAFLD)相关靶点;采用String数据库构建交集靶点蛋白质-蛋白质相互作用网络模型;运用CytoScape 软件构建“泽泻汤-NAFLD靶点-通路”网络图;利用Metascape平台进行靶点富集分析。建立人肝癌HepG2细胞脂质堆积模型,以吸光度值反映泽泻汤传统汤剂、配方颗粒对细胞脂质堆积的影响。
结果
2
泽泻汤治疗NAFLD的关键活性成分包括泽泻醇B、泽泻醇C、一亚油酸甘油酯、泽泻醇B单乙酸酯等,核心靶点包括MDM2、MAPK1、PIK3CB、PRKCQ、MAPK14等,核心信号通路包括内分泌抵抗、胰岛素抵抗、辅助性T细胞17细胞分化等。与模型组比,除泽泻配方颗粒组、白术配方颗粒组外,各给药组细胞吸光度值均显著降低(
P
<0.01);白术传统汤剂组吸光度值显著高于泽泻汤传统汤剂组(
P
<0.01);泽泻配方颗粒组、白术配方颗粒组吸光度值均显著高于泽泻汤配方颗粒组(
P
<0.01);泽泻配方颗粒组吸光度值显著高于泽泻传统汤剂组(
P
<0.01);白术配方颗粒组吸光度值显著高于白术传统汤剂组(
P
<0.01)。
结论
2
泽泻汤通过多成分、多靶点、多通路降低人肝癌细胞脂质堆积,其传统汤剂与配方颗粒降脂效果略有差异。
OBJECTIVE
2
To explore the effect and mechanism of Zexie tang (ZXT) on reducing lipid accumulation through network pharmacology, and compare the difference of traditional decoction versus formula granules.
METHODS
2
The active components and targets of ZXT were identified using TCMSP and SwissTargetPrediction databases. GeneCards, OMIM, DisGeNET and TTD databases were used to analyze the related targets of non-alcoholic fatty liver disease (NAFLD); protein-protein interaction network model was constructed by String database; “ZXT-NAFLD target-pathway” network diagram was constructed by using CytoScape software; target enrichment analysis was performed by using Metascape platform. Fat accumulation model of human hepatocellular carcinoma HepG2 cells was established to observe the effects of traditional decoction and formula granules of ZXT on lipid accumulation of cells.
RESULTS
2
Alisol B, alisol C, 1-monolinolein and alisol B monoacetate were the key active components of ZXT in the treatment of NAFLD. The core targets included MDM2, MAPK1, PIK3CB, PRKCQ and MAPK14, etc. The core signaling pathways included endocrine resistance, insulin resistance and Th17 cell differentiation. Compared with model group, except for the Zexie formula granules group and Baizhu formula granules group, the absorbance values in all other administration groups were significantly decreased (
P
<0.01); the absorbance value of Baizhu traditional decoction group was significantly higher than that of ZXT traditional decoction group (
P
<0.01); the absorbance values of Zexie formula granule group and Baizhu formula granule group were significantly higher than that of ZXT formula granule group (
P
<0.01); the absorbance value of Zexie formula granule group was significantly higher than that of Zexie traditional decoction group (
P
<0.01); the absorbance value of Baizhu formula granule group was significantly higher than that of Baizhu traditional decoction group (
P
<0.01).
CONCLUSIONS
2
ZXT reduces lipid accumulation of human hepatocellular carcinoma cells through multiple components, multiple target and multiple pathways, and its traditional decoction and formula granules exhibit slightly different lipid-lowering effects.
HAN S K , BAIK S K , KIM M Y . Non-alcoholic fatty liver disease:definition and subtypes [J ] . Clin Mol Hepatol , 2023 , 29 ( Suppl. ): S5 - S16 .
范建高 , 徐小元 , 南月敏 , 等 . 代谢相关(非酒精性)脂肪性肝病防治指南:2024年版 [J ] . 实用肝脏病杂志 , 2024 , 27 ( 4 ): 494 - 510 .
丁剑波 , 李丽 , 李秀惠 . 青少年学生血尿酸水平与非酒精性脂肪性肝病发生、发展的关系 [J ] . 肝脏 , 2025 , 30 ( 1 ): 87 - 90 .
尚敏 , 陈平 , 金志健 , 等 . 非酒精性脂肪性肝炎防治新思路 [J ] . 肝脏 , 2024 , 29 ( 10 ): 1289 - 1291 .
李辉 , 安盟盟 , 张会 , 等 . 司美格鲁肽联合非诺贝特治疗2型糖尿病合并非酒精性脂肪性肝病疗效及安全性观察 [J ] . 陕西医学杂志 , 2025 , 54 ( 3 ): 378 - 383 .
HUANG T D , BEHARY J , ZEKRY A . Non-alcoholic fatty liver disease:a review of epidemiology,risk factors,diagnosis and management [J ] . Intern Med J , 2020 , 50 ( 9 ): 1038 - 1047 .
赵文霞 , 许二平 , 王宪波 , 等 . 非酒精性脂肪性肝炎中医诊疗指南 [J ] . 临床肝胆病杂志 , 2023 , 39 ( 5 ): 1041 - 1048 .
张仲景 . 金匮要略 [M ] . 何任,何若苹,整理.北京 : 人民卫生出版社 , 2005 : 46 .
国家药典委员会 . 中华人民共和国药典:一部 [M ] . 2020年版 . 北京 : 中国医药科技出版社 , 2020 : 239 - 240 .
WU J S , ZHANG F Q , RUAN H N , et al . Integrating network pharmacology and RT-qPCR analysis to investigate the mechanisms underlying Zexie decoction-mediated treatment of non-alcoholic fatty liver disease [J ] . Front Pharmacol , 2021 , 12 : 722016 .
王双双 , 姜恒丽 , 刘烨 , 等 . 经典名方泽泻汤的处方考证及历史沿革分析 [J ] . 中医药学报 , 2023 , 51 ( 9 ): 91 - 96 .
SHI H , ZHENG Y T , ZHAO J M , et al . Zexie decoction reduce glucose-dependent lipid accumulation and oxidative stress in Caenorhabditis elegans [J ] . Phytomedicine , 2023 , 120 : 155036 .
ZHANG F Q , WU J S , RUAN H N , et al . Zexie decoction alleviates non-alcoholic fatty liver disease in rats:the study of genes,lipids,and gut microbiotas [J ] . Biochem Biophys Res Commun , 2022 , 632 : 129 - 138 .
李波 , 张朗赫 , 许梦然 , 等 . 朝鲜淫羊藿酸性多糖的理化特性及对HepG2细胞脂质堆积的改善作用 [J ] . 世界科学技术-中医药现代化 , 2022 , 24 ( 10 ): 3820 - 3827 .
张贵明 , 倪向敏 , 崔涵强 , 等 . 雌马酚干预改善油酸钠诱导的HepG2细胞脂肪变性 [J ] . 陆军军医大学学报 , 2023 , 45 ( 3 ): 202 - 208 .
李冠文 , 王辉敏 , 杨金梅 , 等 . 马齿苋多不饱和脂肪酸成分分析及对HepG2细胞脂质堆积的影响 [J ] . 食品工业科技 , 2022 , 43 ( 15 ): 352 - 358 .
甘露珍 , 姜琼 , 饶志威 , 等 . 泽漆醇提取物抗氧化活性及对油酸诱导HepG2细胞脂质堆积的影响 [J ] . 食品工业科技 , 2024 , 45 ( 6 ): 330 - 336 .
林欣欣 , 张鸿燕 , 吴伟铭 , 等 . 泽泻醇B对脂肪细胞分化的影响实验研究 [J ] . 亚太传统医药 , 2023 , 19 ( 9 ): 35 - 39 .
罗燕 , 和兴萍 , 李雪 , 等 . 几种细胞脂肪变性模型的建立与比较分析 [J ] . 中华中医药学刊 , 2017 , 35 ( 8 ): 2074 - 2077 .
RU J L , LI P , WANG J N , et al . TCMSP:a database of systems pharmacology for drug discovery from herbal medicines [J ] . J Cheminform , 2014 , 6 : 13 .
PIÑERO J , RAMÍREZ-ANGUITA J M , SAÜCH-PITARCH J , et al . The DisGeNET knowledge platform for disease genomics:2019 update [J ] . Nucleic Acids Res , 2020 , 48 ( D1 ): D845 - D855 .
PIÑERO J , BRAVO À , QUERALT-ROSINACH N , et al . DisGeNET:a comprehensive platform integrating information on human disease-associated genes and variants [J ] . Nucleic Acids Res , 2017 , 45 ( D1 ): D833 - D839 .
PIÑERO J , QUERALT-ROSINACH N , BRAVO À , et al . DisGeNET:a discovery platform for the dynamical exploration of human diseases and their genes [J ] . Database(Oxford) , 2015 , 2015 : bav028 .
WANG Y X , ZHANG S , LI F C , et al . Therapeutic target database 2020:enriched resource for facilitating research and early development of targeted therapeutics [J ] . Nucleic Acids Res , 2020 , 48 ( D1 ): D1031 - D1041 .
WISHART D S , FEUNANG Y D , GUO A C , et al . DrugBank 5.0:a major update to the DrugBank database for 2018 [J ] . Nucleic Acids Res , 2018 , 46 ( D1 ): D1074 - D1082 .
SZKLARCZYK D , GABLE A L , LYON D , et al . STRING v11:protein-protein association networks with increased coverage,supporting functional discovery in genome-wide experimental datasets [J ] . Nucleic Acids Res , 2019 , 47 ( D1 ): D607 - D613 .
TRIPATHI S , POHL M O , ZHOU Y Y , et al . Meta- and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding [J ] . Cell Host Microbe , 2015 , 18 ( 6 ): 723 - 735 .
ZHOU Y Y , ZHOU B , PACHE L , et al . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets [J ] . Nat Commun , 2019 , 10 ( 1 ): 1523 .
阿曼古丽·艾则孜 , 马红梅 , 兰卫 . 洋甘菊总黄酮对HepG2细胞脂质沉积的改善作用研究 [J ] . 中国药房 , 2022 , 33 ( 11 ): 1306 - 1312 .
董丽红 , 张瑞芬 , 黄菲 , 等 . 油酸诱导单纯性肝脂肪变性细胞模型的建立及应用 [J ] . 中国药理学通报 , 2017 , 33 ( 11 ): 1622 - 1626 .
卢晓臣 , 韩红梅 . 非酒精性脂肪性肝病体外模型的研究进展 [J ] . 临床肝胆病杂志 , 2022 , 38 ( 1 ): 201 - 205 .
鲍洋 , 田琳洁 , 张定堃 , 等 . 中药配方颗粒低制成比问题分析及解决思路研究 [J ] . 中药材 , 2025 , 48 ( 1 ): 253 - 260 .
陈盛君 , 李松 , 过科家 , 等 . 中药配方颗粒国家药品标准技术特点探讨 [J ] . 中国实验方剂学杂志 , 2025 , 31 ( 10 ): 256 - 264 .
钟雨虹 , 惠玉玉 , 田文丽 , 等 . 经典名方中药复方颗粒剂制备技术的研究进展 [J ] . 天津中医药大学学报 , 2024 , 43 ( 8 ): 745 - 751 .
王龙 , 高鑫 , 闫信豪 , 等 . 中药配方颗粒研发生产中若干关键问题研究进展 [J ] . 中南药学 , 2022 , 20 ( 9 ): 2008 - 2014 .
孙定人 , 张石革 . 中成药内科疾病用药:补益剂 [J ] . 中国药房 , 2001 , 12 ( 10 ): 58 - 61 .
谭清立 , 李佳怡 , 林岱衡 . 我国中药配方颗粒的政策工具分析及优化研究 [J ] . 中国药房 , 2023 , 34 ( 22 ): 2689 - 2694 .
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution